Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Sabina Signoretti, M.D.

Co-Author

This page shows the publications co-authored by Sabina Signoretti and Glenn Bubley.
Connection Strength

0.222
  1. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 06; 92(23):1918-25.
    View in: PubMed
    Score: 0.058
  2. Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2020 Oct; 52(10):1132.
    View in: PubMed
    Score: 0.058
  3. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.037
  4. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul; 45(7):747-55.
    View in: PubMed
    Score: 0.035
  5. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.